ONCOLOGY

PIK3CA mutation status predicted resistance to cetuximab.

Phase 2 trial shows efficacy regardless of high-risk HPV type.

Data from the phase 2 pembrolizumab KEYNOTE-158 basket study.

HIV coinfection increases HPV-related cancer risk.

The campaign aims to improve uptake by encouraging women to attend screening.

Safety, efficacy not established; some evidence points to lower long-term survival.

Rapid worldwide scale-up could virtually eliminate the disease by century's end.

Findings affirm public health benefits.

Findings from the pilot project strongly support an extension of screening intervals.

Experts say a new algorithm could revolutionise cervical cancer screening.

Overall cancer risk boosted by 28%.

Testing intervals often longer than recommended.

Study closed because of a higher death rate vs open surgery.

Cancer survival rates in US declined after adoption of MIS.